Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial - PubMed
5 hours ago
- #KRASG12C inhibitor
- #first-line NSCLC
- #combination therapy
- Combination of fulzerasib (a KRASG12C inhibitor) and cetuximab (an anti-EGFR antibody) showed a 69% objective response rate in previously untreated KRASG12C-mutated NSCLC patients in the phase 1b/2 KROCUS trial.
- The safety profile was favorable, with treatment-related adverse events occurring in 87% of patients, primarily grade 1-2; only 15% experienced grade 3 events, and no grade 4 or 5 events were reported.
- The combination is planned for further evaluation in a phase 3 study, supporting its potential as a first-line therapy for KRASG12C-mutated NSCLC based on encouraging efficacy and manageable toxicity.